Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
March 21, 2019 16:29 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
March 18, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference
March 04, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs
February 27, 2019 16:30 ET
|
Translate Bio, Inc.
-- Initiated multiple-ascending dose portion of the Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis -- -- Received FDA communication related to previously announced IND clinical...
Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
February 14, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
January 22, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
January 03, 2019 07:30 ET
|
Translate Bio, Inc.
-- Received approval to begin multiple-ascending dose in Phase 1/2 clinical trial of MRT5005, an mRNA therapeutic for CF -- -- Submitted IND for Phase 1/2 clinical trial of MRT5201, an mRNA...
Translate Bio Appoints Robert Meyer, MD, to its Board of Directors
January 03, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)
December 04, 2018 09:15 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
November 08, 2018 16:21 ET
|
Translate Bio, Inc.
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...